Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays

2004 ◽  
Vol 203 (1) ◽  
pp. 584-593 ◽  
Author(s):  
Harriet Wikman ◽  
Jouni K Seppänen ◽  
Virinder K Sarhadi ◽  
Eeva Kettunen ◽  
Kaisa Salmenkivi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tissue Microarrays ◽  
Tumour Markers ◽  
Combined Use

ACTH, calcitonin and ADH as tumour markers in lung cancer

1984 ◽  
Vol 104 (4_Supplb) ◽  
pp. S57
Author(s):  
W. WINKELMANN ◽  
U. DEUSS ◽  
W. HUMMERICH ◽  
D. KAULEN ◽  
H. BROSCH ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tumour Markers

scholarly journals Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?

1995 ◽  
Vol 72 (1) ◽  
pp. 170-173 ◽  
Author(s):  
M Plebani ◽  
D Basso ◽  
F Navaglia ◽  
M De Paoli ◽  
A Tommasini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Clinical Evaluation ◽  
Cancer Diagnosis ◽  
Tumour Markers ◽  
Lung Cancer Diagnosis

Combined Use of Autofluorescence Bronchoscopy and Argon Plasma Coagulation Enables Less Extensive Resection of Radiographically Occult Lung Cancer

Respiration ◽  
2004 ◽  
Vol 71 (4) ◽  
pp. 410-411 ◽  
Author(s):  
Bart Schuurman ◽  
Pieter E. Postmus ◽  
Johan C. van Mourik ◽  
Elle K. Risse ◽  
Thomas G. Sutedja
Keyword(s):  
Lung Cancer ◽  
Argon Plasma Coagulation ◽  
Argon Plasma ◽  
Extensive Resection ◽  
Plasma Coagulation ◽  
Combined Use ◽  
Autofluorescence Bronchoscopy

Establishment and clinical application of a highly sensitive TAT-2 time-resolved fluorescence immunoassay detection

2021 ◽  
Author(s):  
Xindong Chen ◽  
Jianfeng Hong ◽  
Han Zhao ◽  
Zhongyi Xiang ◽  
Yuan Qin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Nasopharyngeal Cancer ◽  
Reaction Rates ◽  
Measurement Range ◽  
Fluorescence Immunoassay ◽  
Time Resolved Fluorescence ◽  
Time Resolved ◽  
Combined Use ◽  
Highly Sensitive ◽  
Positive Rate

Abstract Background: A rapid and highly sensitive assay for tumor-associated trypsinogen-2 (TAT-2) based on the time-resolved fluorescence immunoassay (TRFIA) detection technique was developed for the determination of serum TAT-2 levels in cancers. Results: The measurement range of TAT-2-TRFIA was 1.53-300 ng/mL. The within-run and between-run coefficients of variation of TAT-2-TRFIA were 4.38% and 7.82%, respectively. The recovery rate of TAT-2-TRFIA was 103.0%. The cross-reaction rates of trypsin and T-cell immunoglobulin mucin 3 were 0.02% and 0.82%, respectively. The TAT-2-positive rates in lung cancer, liver cancer, nasopharyngeal cancer, cholangiocarcinoma, brain cancer, and pancreatic cancer were 45.9%, 50.0%, 45.0%, 64.3%, 50.0%, and 41.7%, respectively, with the areas under ROC curves of 0.788, 0.734, 0.862, 0.720, 0.887, and 0.585, respectively. In patients with lung cancer, the positive rate of the single indicator CEA was 28.4%, which increased to 60.6% after combined use with TAT-2. In patients with cholangiocarcinoma, the positive rate of CA-199 was 35.7%, which increased to 71.4% after combined use with TAT-2. Conclusions: TAT-2 is expected to be used as an auxiliary diagnostic indicator for the combined use of tumor markers to improve the positive rate and accuracy of detection.

Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma

2003 ◽  
Author(s):  
Daniel Ayude ◽  
Gloria Gacio ◽  
María Páez De La Cadena ◽  
Estrella Pallas ◽  
Vicenta Martínez-Zorzano ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Tumour Markers ◽  
Neck Squamous Cell Carcinoma ◽  
Combined Use

scholarly journals Combined use of salivary biomarkers and carcinoembryonic antigen for lung cancer detection in a Chinese population

Medicine ◽  
2019 ◽  
Vol 98 (31) ◽  
pp. e16511 ◽  
Author(s):  
Xi Shang ◽  
Huanpu Zi ◽  
Yangyang Li ◽  
Yu Gao ◽  
Changsheng Ge ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Carcinoembryonic Antigen ◽  
Cancer Detection ◽  
Chinese Population ◽  
Salivary Biomarkers ◽  
Combined Use ◽  
Lung Cancer Detection

Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers

Respirology ◽  
2014 ◽  
Vol 19 (5) ◽  
pp. 707-713 ◽  
Author(s):  
Huaping Dai ◽  
Jianqun Liu ◽  
Lirong Liang ◽  
Chengjun Ban ◽  
Jing Jiang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Cancer Risk ◽  
Lung Disease ◽  
Lung Cancer Risk ◽  
Tumour Markers ◽  
Serum Tumour

Tumour markers in bronchial lavage in lung cancer

1993 ◽  
Vol 29 ◽  
pp. S245
Author(s):  
J. Zaleska ◽  
M. Pirozynski ◽  
S. Kwiek ◽  
E. Rowinska-Zakrzewska
Keyword(s):  
Lung Cancer ◽  
Tumour Markers ◽  
Bronchial Lavage

External validation of a panel of plasma microRNA biomarkers for lung cancer

2019 ◽  
Vol 13 (18) ◽  
pp. 1557-1564 ◽  
Author(s):  
Jin Li ◽  
HongBin Fang ◽  
Fang Jiang ◽  
Yang Ning
Keyword(s):  
Lung Cancer ◽  
Early Stage ◽  
External Validation ◽  
Early Stage Lung Cancer ◽  
Combined Use ◽  
Diagnostic Values ◽  
Plasma Microrna ◽  
Diagnosis Of Lung Cancer ◽  
Lung Cancer Detection ◽  
Plasma Mirnas

Aim: We externally validate plasma miRNAs biomarkers for lung cancer in a large and retrospective sample set collected from a geographically distant population. Methods: Plasma samples are tested blindly to the clinical annotations by using PCR for quantitation of the four miRNAs in cohort 1 consisting of 232 lung cancer cases and 243 controls and cohort 2 comprising 239 cases and 246 controls. Results: Combined use of the four plasma miRNAs has 91% sensitivity and 95% specificity for diagnosis of lung cancer, and 85% sensitivity for early-stage lung cancer, while maintaining a specificity of 95%. Conclusion: The diagnostic values of the biomarkers are reproducibly confirmed in the independent and large sample sets, providing an assay for lung cancer detection.

Tumour markers and oncogenes in lung cancer

1991 ◽  
Vol 27 (10) ◽  
pp. 1323-1327 ◽  
Author(s):  
Tomi P Mäkelä ◽  
Karin Mattson ◽  
Kari Alitalo
Keyword(s):  
Lung Cancer ◽  
Tumour Markers
Sign in / Sign up

Export Citation Format

Share Document